For years, people taking GLP-1 type drugs (e.g., Ozempic, Wegovy) have noticed that the medicines didn’t just help them to ...

A phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving with low-dose semaglutide. HealthDay News — Low-dose semaglutide seems to reduce craving and certain ...

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

But the newest study that has gone viral is an even more impressive outcome. Headlines are claiming that researchers have ...

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

showed improvements in certain measures of alcohol use disorder during a nine-week trial. The Danish drugmaker is also testing semaglutide - sold as the diabetes drug Ozempic and the obesity drug ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...